BERKELEY,CA – Nov 8, 2018 – PRNewswire
Actym Therapeutics, a privately held biotechnology company focused on therapeutic targeting of intractable immune pathways in the tumor microenvironment, announced today that it will be presenting data at the upcoming Society for Immunotherapy of Cancer (SITC) annual meeting in Washington, D.C. from November 9-11, 2018. The presentation is titled “STACT-TREX1: A novel tumor-targeting systemically-delivered STING pathway agonist demonstrates robust anti-tumor efficacy in multiple murine cancer models.”
“We look forward to sharing data demonstrating the potent anti-tumor activity of our first-in-class STING pathway agonist therapy, STACT-TREX1, in preclinical models. We are encouraged by the data showing that single-agent treatment with STACT-TREX1 generates tumor antigen-specific CD8+ T cell responses, suggesting induction of adaptive anti-tumor immunity after intravenous administration in mice. We believe this mechanism for activating the STING pathway in the tumor microenvironment represents a novel and superior approach for the treatment of cancer.” said Dr. Christopher Thanos, President and CEO of Actym Therapeutics.
Details of the presentation is as follows:
STACT-TREX1: A novel tumor-targeting systemically-delivered STING pathway agonist demonstrates robust anti-tumor efficacy in multiple murine cancer models
Date: November 9, 2018
Location: Hall E, Walter E. Washington Convention Center
For those unable to attend the conference who would like a copy of the presentation, please send an email request to [email protected]. Please include your name, company, title and phone number. The presentation will be emailed to those making proper requests after November 10, 2018.
Actym Therapeutics, Inc. is an immunotherapy company focused on the discovery and development of novel therapies that are intended to transform the treatment of cancer. Actym’s STACT technology platform is designed to harness the body’s natural immune system to modify the tumor microenvironment. STACT allows for targeting immune pathways that are intractable using conventional small molecule or antibody-based therapeutics. Actym’s STACT-TREX1 lead therapeutic candidate is designed to reduce TREX1 activity in the tumor microenvironment and activate the STING pathway, which results in a potent anti-tumor immune response in preclinical models. For more information, please visit: www.actymthera.com.